A recombinant adeno-associated virus (rAAV) vector was used to overexpress the anti-apoptotic Bcl-2-family protein, BCL-w, in rat brain. Three weeks after injecting the vector into cerebral cortex and striatum on one side, temporary focal ischemia was induced by occlusion of the ipsilateral middle cerebral artery for 90 min, followed by reperfusion for 24 h. BCL-w expression was increased in cerebral cortex and striatum -and in neurons, astroglia and endothelial cells -in the brains of rats that received the rAAV-BCL-w vector, compared to rats given phosphate-buffered saline or a control vector containing the gene for green fluorescent protein. Recipients of the rAAV-BCL-w vector also showed a 30% reduction in infarct size and a 33-40% improvement in neurological function, compared to the control groups. These results provide evidence for a role of BCL-w in regulating histological and functional outcome after focal cerebral ischemia.
Introduction
The Bcl-2 family of proteins comprises both antiapoptotic and pro-apoptotic members, and hetero-and homodimerization of Bcl-2-related proteins play a pivotal role in physiological and pathological cell death triggered by caspases.
1,2 BCL-w is a recently identified member of this family that resides on human chromosome 14 at band q11. 3 Overexpression of Bcl-w renders lymphoid and myeloid cells refractory to several cytotoxic insults, 3 whereas Bcl-w-null animals exhibit increased apoptosis in intestinal epithelium 4 and impaired spermatogenesis. 5 Therefore, like Bcl-2 and Bcl-x, Bcl-w protein promotes cell survival, in contrast to Bax, Bad, Bim and Bak, which facilitate cell death. 2 Bcl-w may also have an anti-apoptotic role in the nervous system since in many cases, neuronal cell death is regulated by competitive interactions between proand anti-apoptotic proteins of the Bcl-2 family. 2 Overexpression of Bcl-w in sympathetic neurons prevents death from nerve growth factor deprivation 6 and promotes neuronal survival in the absence of neurotrophins, while microinjection of Bcl-w antisense constructs reduces neuronal survival in the presence of neurotrophins. 7 Our previous results showed that Bcl-w protein is upregulated after cerebral ischemia in the rat 8 and is particularly abundant in the penumbral region of the cerebral cortex, mainly in cells lacking DNA fragmentation. 9 This raises the possibility that forced expression of Bcl-w protein might rescue neural cells from death due to ischemic cerebral injury. Viral vectors, which are capable of infecting almost every cell in a target population, may provide the most efficient way of delivering genes into mammalian cells, including brain cells. Adeno-associated virus (AAV) is a promising alternative to other vectors currently in use since AAV has high efficiency in delivering genes into brain cells and has limited cytotoxicity. 10, 11 In this study, therefore, a recombinant AAV (rAAV) vector was used to deliver the human BCL-w gene into rat brain. Our results show that overexpression of BCL-w protein improves histological and functional outcome after transient focal cerebral ischemia in an animal model of stroke.
Results

Overexpression of BCL-w mediated by AAV
As previously reported, 8 Bcl-w was expressed at low levels in sham-operated control brains, and increased expression was observed in ischemic brain, particularly in the penumbral region. However, expression of BCL-w protein in ischemic brain, and especially ischemic striatum, was increased dramatically in animals given rAAV/CMV/BCL-w (Figure 1a ) compared to those receiving PBS (Figure 1e ). BCL-w expression was observed in cells with neuronal, glial and endothelial morphology (Figure 1b-d) . In neurons, BCL-w was expressed mainly in the cytoplasm of perikaryon and processes. Counterstaining with hematoxylin showed that cells expressing BCL-w had normal morphology, and that cell survival was closely associated with expression of BCL-w (Figure 1a) . rAAV/BCL-w treat-ment increased neuronal survival in particular, as demonstrated by an increased number of NeuN-immunopositive cells in the ischemic striatum (Figure 1f and  1g) . The identity of BCL-w-expressing cells was confirmed by double immunolabeling with antibodies against cell type-specific markers (Figure 2 ).
Effect of rAAV/CMV/BCL-w on infarct size
To investigate whether AAV-mediated overexpression of BCL-w improved histological outcome after cerebral ischemia, rAAV/CMV/BCL-w was injected into the cortex and striatum at multiple sites, with rAAV/ CMV/gfp and PBS as controls. Ischemia was induced 3 weeks after injection, since AAV-BCL-w was highly expressed at that time, as determined by immunocytochemistry. Infarct size was evaluated 24 h after 90 min of focal ischemia. As shown in Figure 3 , infarct size in sham-operated rats was similar to that in animals receiving rAAV/CMV/gfp prior to ischemia, whereas infarct size in rAAV/CMV/BCL-w-treated rats was 30% smaller. As shown in Table 1 , there were no statistically significant differences in the measured physiological variables among the groups.
Effect of rAAV/CMV/BCL-w on neurological deficits
Neurological deficits were assessed using two wellestablished tests of post-ischemic neurological functionthe neurological grade and the hindlimb placement test.
12 At 24 h after focal ischemia, rAAV/CMV/BCL-w improved neurological grade by 40% compared to rAAV/CMV/gfp-treated rats and by 33% compared to sham-operated controls (Figure 4 ). In addition, rAAV/ CMV/BCL-w improved scores in the hindlimb placement test by 42% compared to both rAAV/CMV/gfptreated rats and sham-operated controls.
Longer-term assessment of rAAV/CMV/BCL-w effect To determine if rAAV/CMV/BCL-w produced lasting changes in the size of cerebral infarcts, as opposed to simply delaying their evolution, some rats were studied Figure 1 rAAV/CMV/BCL-w-driven overexpression of BCL-w in rat brain after focal ischemia. Immunocytochemistry with an antibody against BCL-w showed widespread neuronal expression of BCL-w in vector-treated (a) compared to PBS-treated (e) striatum, with staining of neurons (b), astroglia (c) and endothelial cells (d). In the striatum of rAAV/CMV/BCL-w-treated rats, there was a close association between BCL-w expression and survival (a). The number of NeuN-immunopositive cells in ischemic striatum was increased after rAAV/CMV/BCL-w treatment (f compared to g), consistent with increased survival of neurons in particular.
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Y Sun et al at 1 week rather than 24 h after ischemia. In addition, infarct volume in these rats was measured by hematoxylin instead of TTC staining, substituting a morphological and presumably permanent index of ischemic cell injury for a metabolic and possibly transitory one. Infarct volume measured in PBS-treated control rats was smaller at 1 week than at 24 h, which is consistent with the survival of some tissue in the ischemic penumbra that was metabolically compromised in the acute phase. However, rAAV/CMV/BCL-w still reduced infarct volume by approximately 30% at 1 week ( Figure 5 ). Therefore, overexpression of BCL-w produced long-term changes in histological outcome from cerebral ischemia.
Discussion
In this study, we investigated the effects of overexpressing BCL-w by intracerebral administration of rAAV/ CMV/BCL-w vector to rats undergoing focal cerebral ischemia induced by MCA occlusion. We found that AAV-mediated BCL-w gene transfer led to overexpression of BCL-w protein in neurons, astrocytes and endothelial cells, and significantly reduced infarct size and improved neurological function after ischemia. Constitutive expression of Bcl-w mRNA is low in the normal adult rodent brain, 13, 14 and although its expression is induced after cerebral ischemia, 8, 9 this may still be inadequate to prevent ischemic injury. In contrast, we observed high levels of rAAV vector-mediated expression of BCL-w protein in multiple cell types at 3 weeks in our rats. Since ischemic injury was widely distributed, involving both cerebral cortex and striatum, we administered rAAV/CMV/BCL-w at multiple injection sites. The resulting histological and functional improvement was comparable in magnitude to that observed after overexpression of other Bcl-2-family proteins. 15, 16 It is reasonable to ask whether these findings have any implications for clinical disease, since animal models of stroke have predicted the clinical usefulness of some (eg thrombolytic) but not other (eg anti-excitotoxic) therapies. 17 However, the administration of anti-excitotoxic drugs in clinical studies of stroke has generally been delayed beyond the therapeutic window predicted from animal studies, and the failure of clinical trials involving such drugs has often resulted from adverse effects or marketing considerations, and not always from lack of efficacy. 18 In addition, clinical stroke is a heterogeneous disorder, which could mask a beneficial effect of treatment in a subset of patients. 19 Therefore, although the most direct implications of this study relate to the basic biology of ischemic neuronal injury, it may also prove to have clinical significance.
Although a variety of gene transfer techniques have been developed, none approaches the efficiency of viruses in terms of the percentage of cells that can be transfected and the fraction of DNA molecules that can be introduced into recipient cells, particularly in the case of post-mitotic cells like neurons. In recent years, AAV vectors have become increasingly popular as vehicles for efficient gene transfer into mammalian AAV-mediated delivery of BCL-w in brain ischemia Y Sun et al cells, since AAV vectors do not contain viral coding sequences and because no expression of viral proteins is found. AAV can also introduce foreign DNA into many cell types without inducing inflammation. Finally, AAV can express inserted DNAs in the central nervous system for long periods, yielding more stable expression in vivo than, for example, herpes simplex virus (HSV). 20 One problem with rAAV is the efficient production of recombinant virions. Therefore, we used a simplified method for generating rAAV by establishing neomycinresistant cell lines containing copies of the AAV rep-cap genes and an rAAV vector. 21 After infection with adenovirus, these cell lines produced infectious rAAV in relatively high titer. This method eliminates the need for exogenous DNA transfection, and scale-up procedures are limited only by the normal constraints of growing cells in culture. 21, 22 The molecular mechanisms through which BCL-w protein protects cells from ischemic injury remain unclear. However, cell death appears to be regulated partly by competitive interactions between pro-and antiapoptotic Bcl-2-family proteins, [23] [24] [25] 
Data shown are mean values 7 s.d. from 4 to 6 rats per condition. MABP, mean arterial blood pressure; PaO 2 , partial pressure of O 2 in arterial blood; PaCO 2 , partial pressure of CO 2 in arterial blood; pH, arterial blood pH; Glucose, plasma concentration of glucose. There were no significant differences across treatment groups for any of the variables examined.
AAV-mediated delivery of BCL-w in brain ischemia Y Sun et al neuronal death after ischemia. Bcl-w can bind to the proapoptotic Bcl-2-family proteins Bax, Bak, Bad and Bik, and protects against apoptosis induced by overexpression of Bax or Bad. 27, 28 Moreover, the competitive effects of pro-and anti-apoptotic Bcl-2-family proteins regulate the activation of caspases, which have also been implicated in ischemic neuronal death. [29] [30] [31] The results of our study provide additional evidence for a programmed component of cell death in cerebral ischemia, and point to BCL-w as another potential target for novel therapeutics in stroke. Whether such targeting could best be achieved by AAV-mediated gene therapy or by another approach, such as administration of a drug that modifies BCL-w expression, remains to be determined.
Materials and methods
Production of rAAV/CMV/BCL-w
Recombinant AAV/CMV/BCL-w was isolated from a stable HeLa producer cell line (F7) as described previously. 21, 22 Stable rAAV producer cell lines were generated by cloning the PCR-generated BCL-w cDNA sequence into the NotI sites of plasmid pAAV/CMV/repcap/neo-tk. This resulted in the generation of a 13.8-kb tripartite plasmid that consisted of (i) AAV-2 rep and cap sequences, (ii) an rAAV vector cassette containing the hCMV immediate early promoter and BCL-w cDNA flanked by AAV inverted terminal repeats, and (iii) a neomycin-resistance gene. Following tripartite plasmid transfection of HeLa cells, 192 G418-resistant cell lines were isolated and an optimal producer line was selected based on the ability to produce high-titer rAAV in response to infection with adenovirus type 5 (Ad 5) at a multiplicity of infection (moi) of 20. Large-scale viral production was accomplished by growing F7 cells to high density (410 10 cells) in an adherent cell bioreactor (Cell Cube, Corning Inc.) and infecting the cells with Ad 5 at moi¼20. Following development of the Ad 5-induced cytopathic effect, cells were collected and pelleted at 2000 g for 15 min at 41C. The cell pellet was resuspended in 20 mM Tris (pH 8.0) and 150 mM NaCl at a cell density of 5 Â 10 6 cells/ml. To achieve efficient cell lysis, deoxycholate detergent was added to a final concentration of 0.5% and incubated for 30 min at 371C. Lysate viscosity was reduced by the addition of 50 units/ ml of benzonase (American International Chemical) concurrent with deoxycholate incubation. Cellular debris was removed by centrifugation at 3000 g for 15 min at 41C. The clarified lysate was heated to 561C for 45 min to inactivate contaminating adenovirus. The lysate was then frozen at À201C overnight. Upon thawing, a flocculent precipitate was observed, and was removed by centrifugation at 3000 g for 10 min. To remove any remaining particulates that might interfere with subsequent column purification, the clarified lysate was filtered through a 2 mm disc filter. The clarified lysate was passed over a POROS HE1/M heparin column using a Biocad Sprint HPLC machine (PE Applied Biosystems) at a flow rate of 3 ml/min. The column was washed with 50 ml of 20 mM Tris (pH 8.0) and 150 mM NaCl, and virus was eluted with a linear NaCl gradient (0.15-1.0 M). A single dominant protein peak was eluted at B0.4 M NaCl and the viruscontaining fractions were pooled and dialyzed against multiple changes of 20 mM Tris (pH 8.0), 1 mM MgCl 2 and 150 mM NaCl and stored at À801C in 5% glycerol.
Titration of rAAV/CMV/BCL-w
DNase resistant particles (DRP) were determined using quantitative real-time Taqman PCR (PE Applied Biosystems Prism 7700 sequence detector system) as previously described. 22 Briefly, the rAAV/CMV/BCL-w stock was diluted by 10 3 and 10 4 in 1 Â PCR Buffer (50 mM KCl, 10 mM Tris-HCl pH 8.3, 5 mM MgCl 2 and 0.01% (w/v) gelatin) and incubated at 371C for 30 min in the presence or absence of DNase I (350 units). The viral samples were subsequently treated with proteinase K (10 mg) for 1 h at 501C. This was followed by a 20-min incubation at 951C to inactivate proteinase K, after which 2.5 ml of the digested viral sample was added to 22.5 ml of a standard Taqman master mix (PE Applied Biosystems), and each viral sample was run in triplicate. Concurrently, a DNA plasmid standard curve was set up in triplicate using 10 1 -10 6 AAV genome equivalents. Because the AAV genome is single stranded, the plasmid standard curve , and then by 400 to derive a titer per ml (2.5 ml Â 400¼1 ml). All plasmid DNA concentrations were determined by fluorometric Hoescht dye readings. The DRP titer of the rAAV/CMV/BCL-w (CC71) used for all the experiments described was 5.2 Â 10 13 DRP/ml. The absence of replication-competent adenovirus was confirmed by passing 1% of the purified rAAV/CMV/ BCL-w stock onto 293 cells for 7 days and scoring for adenovirus cytopathic effect. The presence of wild-typelike AAV was assessed by passing 1% of the rAAV stock onto HeLa cells (2 Â 10 5 ) in the presence of adenovirus (moi¼20). Forty-eight hours later, Hirt DNA was isolated and Southern blot hybridization was performed using a portion of the cap gene as the hybridization probe. Control experiments demonstrated that the level of sensitivity in this passage assay was 1 wild-type AAV infectious unit. The failure to detect monomeric and dimeric replicative intermediates in our rAAV vector stocks was taken as evidence that contamination with wild-type-like AAV is p100 IU/rAAV preparation.
AAV delivery
Animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult male Sprague-Dawley rats (280-310 g) were anesthetized by face mask with 4% isoflurane in 70% N 2 O and 30% O 2 and placed in stereotaxic frames with a rat head holder. Two burr holes were drilled while the dental drill was irrigated continuously with saline at room temperature to prevent overheating of the underlying cortex. rAAV/CMV/BCLw (5.2 Â 10 13 DRP/ml), rAAV/CMV/green fluorescent protein (gfp), or PBS was infused into the left cerebral cortex (0.48 mm anterior to bregma, 5.5 mm lateral to midline, 6 mm deep from dura) and left striatum (0.48 mm anterior to bregma, 3.5 mm lateral to the midline and 6 mm deep from dura) in a volume of 3 ml over 2 min. The needle was left in place (3.5 mm deep from dura for left cerebral cortex; 4.5 mm deep from dura for left striatum) for 2 min, another injection was performed, and the needle was left in place for an additional 5 min. Following the injections, bone wounds were closed with bone wax. Anesthesia was discontinued, and rats were returned to their cages. Transient focal cerebral ischemia was induced 3 weeks later.
Focal cerebral ischemia
Transient focal ischemia was induced using the suture occlusion technique as described previously. 32, 33 Adult male Sprague-Dawley rats (280-310 g) were anesthetized as described above, a midline incision was made in the neck, and the right external carotid artery (ECA) was carefully exposed and dissected. A 3-0 monofilament nylon suture (19 mm long) was inserted from the ECA to the right internal carotid artery to occlude the origin of right middle cerebral artery (MCA). After 90 min of occlusion, the thread was removed to allow reperfusion, the ECA was ligated, and the wound was closed. Shamoperated rats underwent identical surgery except that the suture was not inserted. Rectal temperature was maintained at 37.0 7 0.51C using a heating pad and heating lamp. Blood pressure and blood glucose concentration were also monitored. Rats were killed 24 h or 1 week after 90 min of MCA occlusion; they were anesthetized and perfused through the heart with 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4), brains were removed, and cellular morphology was examined by cresyl violet staining.
Immunocytochemistry
Sham-operated or ischemic brains with and without prior AAV injection (n¼4 per experimental condition) were perfused with 0.9%. saline followed by 4% 
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Y Sun et al paraformaldehyde in PBS (pH 7.4), and embedded in paraffin. The paraffin-embedded sections (6 mm thick) were deparaffinized with xylene and rehydrated with ethanol. Immunocytochemistry was performed as previously described. 34 In brief, after blocking endogenous peroxidase activity with 1% H 2 O 2 , sections were incubated with blocking buffer (2% horse serum, 0.2% Triton X-100 and 0.1% bovine serum albumin in PBS) for 1 h at room temperature. Sections were then incubated overnight at 41C with a rabbit polyclonal antibody against BCL-w (Chemicon, 1:200). The secondary antibody was a biotinylated goat anti-rabbit IgG (Vector, 1:200). Sections were processed with a Vector ABC kit according to the manufacturer's instructions. The horseradish peroxidase reaction was detected by incubation with diaminobenzidine and H 2 O 2 . Alternating sections were incubated without primary antibody as a control.
Double fluorescence labeling
Deparaffinized sections were incubated with blocking buffer for 1 h at room temperature, and subsequently with a mixture of two primary antibodies: rabbit anti-BCL-w (1:1000) and either mouse anti-NeuN (Chemicon, 1:500) or anti-GFAP (Sigma, 1:1000) at 41C overnight. After washing three times for 10 min each in PBS, the sections were incubated with secondary antibodies: fluorescein isothiocyanate (FITC)-conjugated goat antirabbit or anti-mouse IgG (Vector, 1:200) or rhodamineconjugated rat-absorbed donkey anti-mouse or antirabbit IgG diluted (Jackson ImmunoResearch, 1:200). Fluorescence signals were detected with a Nikon E800 epifluorescence microscope (Nikon Inc, Melville, NY, USA) using excitation/emission wavelengths of 535/ 565 nm for rhodamine (red) and 470/505 for fluorescein isothiocyanate (green). Results were recorded with a Magnifire digital color camera (ChipCoolers Inc., Warwick, RI, USA).
Quantification of infarct volume
Twenty-four hours after MCA occlusion, rats were anesthetized with isoflurane as described above and decapitated. Brains were removed and sectioned coronally at 2-mm intervals in a cryostat. Sections were incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC) in saline for 20 min at 37 1C and transferred to 4% paraformaldehyde overnight. In some experiments, rats were killed 1 week after MCA occlusion and anesthetized and perfused through the heart with 4% paraformaldehyde in PBS, pH 7.4; brains were then removed and stained with hematoxylin to delineate infarct area. To determine infarct volume at 24 h by TTC staining or at 1 week by hematoxylin staining, six sections per rat were analyzed by a blinded observer using the NIH Image program. To correct for the effects of the cerebral edema and of differential shrinkage resulting from tissue processing, the infarction area in each section was calculated by subtracting the area of the healthy, uninfarcted (TTC-or hematoxylin-stained) tissue in the ipsilateral hemisphere from the area of the contralateral hemisphere as described previously. 35 Infarction volume was determined by summing the infarction areas of all sections and multiplying by the slice thicknesses.
Neurological assessment
Twenty-four hours after MCA occlusion, the neurological status of each rat was evaluated according to a neurological grading score of 0-3, as previously described. 36 Grades were based on the degree of contralateral hemiparesis: 0 (no observable deficit), 1 (any amount of consistent contralateral forelimb flexion), 2 (reduced resistance to lateral push toward the paretic side), or 3 (circling behavior toward the paretic side). Functional outcome was also assessed using the hindlimb placement test, 37 in which the rat is held facing away from the edge of a table, and the hindlimb is pulled over the edge of the table and extended downward. A normal response is immediate placement of the hindlimb back onto the table, whereas an abnormal response is no limb placement or movement. Scores are: 0 (complete, immediate placement), 1 (incomplete or delayed placement or both), or 2 (no placement).
Statistical analysis
All values were expressed as the mean 7 s.e.m. Differences among means were analyzed using one-way analysis of variance (ANOVA), and pair-wise comparisons between means were tested by the Scheffe post hoc test. A level of Po0.05 was considered statistically significant.
